Last reviewed · How we verify
Coprelotamab Injection
At a glance
| Generic name | Coprelotamab Injection |
|---|---|
| Also known as | GB221 |
| Sponsor | Genor Biopharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection (PHASE1, PHASE2)
- Clinical Trial of Comparative Study of GB221 Pharmacokinetics (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Coprelotamab Injection CI brief — competitive landscape report
- Coprelotamab Injection updates RSS · CI watch RSS
- Genor Biopharma Co., Ltd. portfolio CI